Name in SEC filings: IMMUCELL CORP /DE/
| Program | Event | Stage | Stated timing | Filing |
|---|---|---|---|---|
| unaudited financial results for the quarter and year ended December 31, 2025 | Financial results | Stage not stated | March 4, 2026 | 8-K · |
| Re-Tain | Other | Stage not stated | first quarter of 2026 | 10-Q · |
| Unaudited financial results for the quarter and nine months ended September 30, 2026 | Financial results | Stage not stated | November 13, 2026 | 8-K · |
| Audited annual financial statements | Financial results | Stage not stated | Wording in the quote below | 10-K · |
| Re-Tain | Other | Stage not stated | Wording in the quote below | 10-Q · |
Source: ORION, orionbiotechai.com/company/ICCC, data as of Oct 15, 2026
https://www.orionbiotechai.com/company/ICCC
Unaudited financial results for the quarter and nine months ended September 30, 2026 · Financial results · November 13, 2026
SEC sources last checked .
○ Quote matched to filing (not yet reviewed by founder) · ✓ Checked by founder.
Financial resultsMarch 4, 2026
Stage: Not stated
Public float: $50,600,000 · as of · SEC filing
On March 4, 2026 ImmuCell Corporation (the "Company") issued a press release announcing its unaudited financial results for the quarter and year ended December 31, 2025.
8-K · Filed · Last checked
Resolution filing: · SEC filing
Alert me · Calendar: same stage and window-end month (2026-03)
Otherfirst quarter of 2026
Study and data analysis completion target
Stage: Not stated
Public float: $50,600,000 · as of · SEC filing
It is our objective to complete the study and data analysis during the first quarter of 2026.
SEC timing context:
During the second half of 2025, we are testing market acceptance of Re-Tain ® in collaboration with Michigan State University through Investigational Product use with inventory on hand that now has a relatively short shelf life.
10-Q · Filed · Last checked
Alert me · Calendar: same stage and window-end month (2026-03)
Financial resultsNovember 13, 2026
Stage: Not stated
Public float: $50,600,000 · as of · SEC filing
The Company is planning to host a conference call on Friday, November 13, 2026, at 9:00 AM ET to discuss the unaudited financial results for the quarter and nine months ended September 30, 2026.
8-K · Filed · Last checked
Alert me · Calendar: same stage and window-end month (2026-11)
Financial resultsNo date stated
Stage: Not stated
Public float: $50,600,000 · as of · SEC filing
We have audited the accompanying balance sheets of ImmuCell Corporation (the “Company”) as of December 31, 2025 and 2024, and the related statements of operations, stockholders’ equity, and cash flows for the years ended December 31, 2025 and 2024, and the related notes (collectively referred to as the “financial statements”).
10-K · Filed · Last checked
OtherNo date stated
Stage: Not stated
Public float: $50,600,000 · as of · SEC filing
On December 23, 2025, we made the decision to cease our efforts to obtain FDA approval of Re-Tain ® while continuing the stability testing and investigational studies to evaluate Re-Tain ® performance.
10-Q · Filed · Last checked
Company periods and sentences are quoted as written. A matching disclosure uses the SEC filing date for the same program and event type. As of .
| Program / event | Stated period and SEC wording | Disclosure in stated period |
|---|---|---|
| Unaudited financial results for the quarter and nine months ended September 30, 2026Unaudited financial results | November 13, 2026“The Company is planning to host a conference call on Friday, November 13, 2026, at 9:00 AM ET to discuss the unaudited financial results for the quarter and nine months ended September 30, 2026.” Filed · EX-99.1 | Period not started The stated period has not started yet, so there is nothing to compare. |
| Re-TainOther | no date stated“On December 23, 2025, we made the decision to cease our efforts to obtain FDA approval of Re-Tain ® while continuing the stability testing and investigational studies to evaluate Re-Tain ® performance.” Filed · 10-Q | No date given This sentence gives no date, so there is no period to compare with filings. |
| Audited annual financial statementsAudited financial results | no date stated“We have audited the accompanying balance sheets of ImmuCell Corporation (the “Company”) as of December 31, 2025 and 2024, and the related statements of operations, stockholders’ equity, and cash flows for the years ended December 31, 2025 and 2024, and the related notes (collectively referred to as the “financial statements”).” Filed · 10-K | No date given This sentence gives no date, so there is no period to compare with filings. |
| unaudited financial results for the quarter and year ended December 31, 2025Unaudited financial results | March 4, 2026“On March 4, 2026 ImmuCell Corporation (the "Company") issued a press release announcing its unaudited financial results for the quarter and year ended December 31, 2025.” Filed · 8-K | Disclosure present SEC filing date within the stated period Filed · 8-K “On March 4, 2026 ImmuCell Corporation (the "Company") issued a press release announcing its unaudited financial results for the quarter and year ended December 31, 2025.” |
| unaudited financial results for the quarter and year ended December 31, 2025Unaudited financial results | February 25, 2026“The Company is planning to release its full, unaudited financial results for the quarter and year ended December 31, 2025 after the market closes on Wednesday, February 25, 2026 and is planning to host a conference call on Thursday, February 26, 2026 at 9:00 AM ET to discuss these results.” Filed · EX-99.1 | No matching disclosure found Completed SEC search through the period end |
| Re-TainOther | no date stated“ImmuCell will complete ongoing investigational studies with Re-Tain ® to assess opportunities for an improved set of claims for preventing and treating mastitis in dairy cows.” Filed · EX-99.1 | No date given This sentence gives no date, so there is no period to compare with filings. |
| Re-TainOther | over the remainder of 2025 and into 2026““On the topic of Re-Tain ®,” Mr. Fiori further commented, “our Investigational Product use of Re-Tain ® is under way, in partnership with Michigan State University. We will continue to collect market feedback about product performance in the field over the remainder of 2025 and into 2026.”” Filed · EX-99.1 | Not compared ORION has no confirmed start and end dates for this wording, so it is not compared with filings. |
| Re-TainOther | no date stated“We expect the FDA to complete its review only after it clears the inspectional observations at the DP facility of our contract manufacturer.” Filed · 10-Q | No date given This sentence gives no date, so there is no period to compare with filings. |
| Re-TainOther | first quarter of 2026“It is our objective to complete the study and data analysis during the first quarter of 2026.” Filed · 10-Q | Not compared The stated period has ended. ORION has no record of a complete search of SEC filings from that period. |
| Re-TainOther | over the second half of 2025 and into the first quarter of 2026““With regards to Re-Tain ® , we have initiated Investigational Product use to collect market feedback about product performance in the field over the second half of 2025 and into the first quarter of 2026,” concluded Mr. Brigham.” Filed · EX-99.1 | Not compared ORION has no confirmed start and end dates for this wording, so it is not compared with filings. |
“Not compared” means ORION has not matched this wording against a complete set of SEC filings for its period. It says nothing either way about whether a matching filing exists. Wording without exact dates is not given calendar dates.
Suggest an SEC timing statement to add for ICCC. You can include the original filing link in your note. The founder reads each request by hand.
Or email ORION.